Overview: Purkinje Cell Antibody Screen TestIntroduction: The Purkinje Cell Antibody Screen Test detects Purkinje cell antibodies to diagnose cerebellar disorders, causing coordination issues. Aligned with 2023 AAN guidelines, it uses immunoassays for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected paraneoplastic cerebellar degeneration.
Other Names: Purkinje Antibody Assay, Cerebellar Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Purkinje cell antibody testing began in the 1980s with paraneoplastic research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Purkinje cell antibodies to diagnose cerebellar disorders, guides treatment, and evaluates patients with coordination issues.
Test Parameters: 1. Purkinje Cell Antibodies
Pretest Condition: No fasting required. Collect serum, CSF, or saliva. Report history of coordination issues or neurological symptoms.
Specimen: Serum (SST, 2-5 mL), CSF (sterile container, 1-2 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document coordination issues, ataxia, or history of cancer/neurological disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, cerebellar disorder implications, and risks of sample collection.
Procedural Considerations: Uses immunofluorescence or ELISA to detect Purkinje cell antibodies. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for cerebellar disorder diagnosis.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other autoantibodies may reduce specificity.
Clinical Significance: Positive antibodies confirm paraneoplastic cerebellar degeneration, guiding cancer workup or immunosuppression. Negative results may require imaging or CSF analysis.
Specialist Consultation: Consult a neurologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, CSF analysis, or paraneoplastic antibody panel to confirm cerebellar disorder diagnosis.
Test Limitations: Non-specific for certain neurological conditions; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Paraneoplastic Guidelines, 2023; Neurology, Dalmau J, 2022.
